Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.
Safety
Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.
See also
- Elafibranor
- GW0742
- GW501516
- MBX-8025
- Peroxisome proliferator-activated receptor
References
